Fig. 1: GNE-493 exerts tumor-suppressive activity in cultured prostate cancer cells.
From: GNE-493 inhibits prostate cancer cell growth via Akt-mTOR-dependent and -independent mechanisms
The patient-derived primary prostate cancer cells (“priCa-1/-2/-3”, that were derived from three patients) or established cell lines (PC-3 or LNCaP) were cultivated in complete medium and stimulated with the applied concentrations of GNE-493 (10–1000 nM) or the vehicle control (0.25% DMSO, “Veh”); cells were further cultivated for a designated time, cell viability (by measuring CCK-8 OD, A and G), the number of cell colonies (B), cell death (by recording the Trypan blue percentage, C and H), and cell proliferation (by recording the EdU-positively stained nuclei percentage, D and I) as well as the in vitro cell migration (“Transwell” assays, E and J) and distribution of cell cycles (PI-FACS assays, F) were tested. *P < 0.05 versus “Veh” group. Scale bar = 100 μm (E).
